Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

2007 Biological New Drug Application (NDA) and Abbreviated New Drug Application (ANDA) Approvals

This list reflects information regarding the supplements as of the approval date. It is not updated with regard to applicant or application status changes. The supplements are listed in order by date of approval.

Established Name
Indication for Use NDA Number Applicant Approval Date
6% Hydroxyethyl Starch 130/0.4 in 0.9% Sodium Chloride Injection (Voluven 500 mL freeflex flexible plastic intravenous solution container)
Treatment and prophylaxis of hypovolemia BN070012 Fresenius Kabi
Deutschland GmbH
Else-Kroner-Strasse 1
61352 Bad Homburg v.d.H., Germany

Page Last Updated: 04/17/2013
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English